Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00087178 · ClinicalTrials.gov registry record · Phase 3

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

A Phase 3 study, sponsored by NSABP Foundation.

Completed
Registry status
Phase 3
Development phase
2,722
Enrollment target

NCT00087178 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 2,722 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00087178, a Phase 3 study, has completed, sponsored by NSABP Foundation.

COMPLETED
Registry status
Phase 3
Development phase
2,722 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating breast cancer. PURPOSE: This randomized phase III trial is studying two combination chemotherapy regimens to compare how well they work in treating women who have undergone surgery for breast cancer that has not spread to the lymph nodes.

Interventions

  • DRUG cyclophosphamide
  • DRUG fluorouracil
  • DRUG epirubicin
  • DRUG adriamycin

Trial Details

FieldValue
Enrollment Target 2,722 participants
Start Date 2004-05
Est. Completion 2016-05
Phase Phase 3

Sponsor

NSABP Foundation

44 total trials

What the Registry Record Tells You About NCT00087178

The ClinicalTrials.gov registry entry for NCT00087178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,722 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.

NCT00087178 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00087178 about?

NCT00087178 is a clinical study titled "Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as fluorouracil, epirubicin, cyclophosphamide, and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating breast cancer. P...

What is the current status of trial NCT00087178?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,722 participants. The study started on 2004-05. Estimated completion is 2016-05.

What interventions are being tested in trial NCT00087178?

The interventions under investigation include: cyclophosphamide (DRUG), fluorouracil (DRUG), epirubicin (DRUG), adriamycin (DRUG).

Who is sponsoring clinical trial NCT00087178?

This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.